

高雄市醫師公會	
收	114.10.27 日
文	字第1587號

檔 號：

保存年限：

中華民國醫師公會全國聯合會 函

地址：106646臺北市大安區安和路1段29號9樓

承辦人：蕭婷婷

電話：(02)2752-7286分機121

傳真：(02)2771-8392

電子信箱：a040827@mail.tma.tw

受文者：如正副本

發文日期：中華民國114年10月23日

發文字號：全醫聯字第1140001383號

速別：普通件

密等及解密條件或保密期限：

附件：如文


主旨：轉知世界衛生組織(WHO)公布劣藥警訊，印度發現不合格口服液劑藥品一案，請查照。

說明：

- 一、依衛生福利部食品藥物管理署114年10月20日FDA藥字第1141401647號函辦理(附件)。
- 二、WHO 114年10月13日公布第5號藥品警訊，印度製造廠(Sresan Pharmaceutical、Rednex Pharmaceuticals及Shape Pharma)所生產3款兒科藥品(COLDRIF、Respifresh TR 及 ReLife)有受二甘醇(diethylene glycol)污染之不合格糖漿情事，可能導致服用後產生腹痛、嘔吐、腹瀉、無法排尿、頭痛、精神狀態改變與可能導致死亡之急慢性腎損傷。
- 三、食品藥物管理署經查，我國未核准前開藥品製造廠相關藥品，亦未有相關專案進口之藥品，評估不影響國內使用，請協助轉知所屬會員務必注意來源與品質，勿使用該等藥品。
- 四、本函訊息刊登本會網站。

正本：各縣市醫師公會、臺灣兒科醫學會

副本：



理事長 陳相國

擬：速刊網站，
發佈至官方社群
胡竹君.114.10.27.

衛生福利部食品藥物管理署 函

地址：115021 臺北市南港區研究院路一段
130巷109號

聯絡人：沈宏璋

聯絡電話：02-2787-7472

傳真：02-2653-2073

電子郵件：hcshe@fda.gov.tw

受文者：中華民國醫師公會全國聯合會

發文日期：中華民國114年10月20日

發文字號：FDA藥字第1141401647號

速別：普通件

密等及解密條件或保密期限：

附件：WHO 114年10月13日第5號藥品警訊 (A21020000I_1141401647_doc2_Attach1.pdf)


主旨：有關世界衛生組織(WHO)公布劣藥警訊，印度發現不合格
口服液劑藥品一案，請依說明段辦理，請查照。

說明：

- 一、依據WHO 114年10月13日第5號藥品警訊(如附件)辦理。
- 二、本署於監控國際藥品警訊發現WHO表示印度製造廠(Sresan Pharmaceutical、Rednex Pharmaceuticals及Shape Pharma)所生產3款兒科藥品(COLDRIF、Respifresh TR 及 ReLife)有受二甘醇(diethylene glycol)污染之不合格糖漿情事，可能導致服用後產生腹痛、嘔吐、腹瀉、無法排尿、頭痛、精神狀態改變與可能導致死亡之急性腎損傷。
- 三、經查藥品許可證資料庫，我國未核准前開藥品製造廠相關藥品，亦未有相關專案進口之藥品，故評估該則警訊不影響我國。
- 四、請貴會協助轉知所屬會員於製造及輸入時應注意相關藥品品質，並勿輸入或使用該等藥品。

正本：中華民國醫師公會全國聯合會、中華民國藥師公會全國聯合會、中華民國藥劑生公會全國聯合會、中華民國基層醫療協會、中華民國區域醫院協會、台灣醫學中心協會、台灣社區醫院協會、中華民國診所協會全國聯合會、台灣醫院協會、社團法人台灣私立醫療院所協會、臺灣醫學會、中華民國西藥商業同業公會全國聯合會、中華民國西藥代理商業同業公會、臺灣製藥工業同業公會、中華民國製藥發展協會、社團法人中華民國學名藥協會、台北市西藥商業同業公會、台北市西藥代理商業同業公會、社團法人臺灣臨床藥學會

副本：



Medical Product Alert N°5/2025

Substandard (contaminated) oral liquid medicines identified in the WHO South-East Asia Region

Alert summary

This WHO Medical Product Alert refers to three substandard (contaminated) oral liquid medicines identified in India and reported to WHO on 8 October 2025.

The affected products are oral liquid medicines containing active ingredients commonly used to relieve symptoms of the common cold, flu, or cough.

On 8 October the Central Drugs Standard Control Organization (CDSCO) of India reported to WHO the presence of Diethylene Glycol (DEG) in at least three oral liquid medicines. This followed information identified by WHO on 30 September 2025 of localized clusters of acute illness and child fatalities in India. CDSCO informed WHO that the contaminated products were reportedly consumed by the affected children.

The **contaminated** oral liquid medicines have been identified to be specific batches of **COLDRIFF, Respifresh TR and ReLife, manufactured by Sresan Pharmaceutical, Rednex Pharmaceuticals, and Shape Pharma.**

CDSCO has confirmed that relevant state authorities have ordered an immediate halt to production at implicated manufacturing sites and have suspended product authorizations. In addition, a recall of the contaminated products has been initiated by relevant state authorities.

The CDSCO has informed WHO that none of the contaminated medicines have been exported from India and there is currently no evidence of illegal export. Nevertheless, WHO encourages National Regulatory Authorities (NRAs) to consider targeted market surveillance, with particular attention to informal and unregulated supply chains where products may circulate undetected. NRAs are also advised to carefully evaluate the risks associated with any oral liquid medicines originating from the same manufacturing sites—particularly those produced since December 2024.

WHO continues to collaborate closely with Indian health authorities to monitor the situation, identify the source of the contamination and mitigate any potential public health risks.

The products identified in this alert are considered substandard as they fail to meet their quality standards and their specifications.

How to identify these substandard (contaminated) products

See annex below with list of affected batches.

Risks

These contaminated products pose significant risks to patients and can cause severe and potentially life-threatening illness. Diethylene glycol is toxic to humans when consumed and can prove fatal. The contaminated oral liquid medicines referenced in this alert are unsafe and their use, especially in children, may result in serious injury or death. Toxic effects can include abdominal pain, vomiting, diarrhoea, inability to pass urine, headache, altered mental state and acute kidney injury which may lead to death.

To protect patients, it is essential to detect and remove these contaminated products from circulation.

Advice to health-care professionals, regulatory authorities and the public

Health-care professionals should report the detection of these substandard products and any incident of adverse effects, or lack of expected effects to their National Regulatory Authorities or National Pharmacovigilance Centre. WHO advises increased surveillance and diligence within the supply chains of countries and regions likely to be affected by these substandard products. Increased surveillance of the informal/unregulated market is also advised.

National regulatory authorities/health authorities, and law enforcement authorities are advised to immediately notify WHO if these products are detected in their country.

If you are in possession of any of these products, WHO recommends that you do not use them. If you, or someone you know, has, or may have, used these products, or suffered an adverse event or unexpected side-effect after use, seek immediate medical advice from a health-care professional or contact a poisons control centre.

All medical products must be obtained from authorized/licensed suppliers. If you have any information about the manufacture or supply of these products, please contact WHO via rapidalert@who.int.

Annex: Products subject of WHO Medical Product Alert N°5/2025

Product	COLDRI	Respifresh TR	Relife
Stated API	paracetamol, phenylephrine chlorpheniramine maleate, phenylephrine, sodium citrate	bromhexine hydrochloride terbutaline sulphate, guaiphenesin, menthol	ambroxol HCL, guaiphenesin terbutaline sulphate, menthol
Manufacturer	Sresan Pharmaceutical manufacturer, No. 787 Bangalore Highways Sunguvarchatraam (Mathura) Kancheepuram, Dist. 602106	Rednex Pharmaceutical Pvt Ltd. Survez No. 586 & 231, NR. SKF Bearing Bavla Bagodra N.H. 8A Kerala, Tal, Bavla, Dist. Ahmedabad-383220 Gujarat	Shape Pharma Pvt. Ltd. Plot No. 4, Surendranagar Rajkot Highway Rd. Shekhpur 363510 Gujarat
Batch	SR-13	R01GL2523	LSL25160
Date of manufacture	05/2025	01/2025	01/2025
Expiry date	04/2027	12/2026	12/2026
Contamination*	48.6% w/v DEG	1.34% w/v DEG	0.61% w/v DEG
Photos	No available photos at this time.		

*As reported by CDSCO